| Molecular detection of cytokeratin-19–positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance A Stathopoulou, I Vlachonikolis, D Mavroudis, M Perraki, C Kouroussis, ... Journal of Clinical Oncology 20 (16), 3404-3412, 2002 | 424 | 2002 |
| A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic … GP Stathopoulos, K Syrigos, G Aravantinos, A Polyzos, P Papakotoulas, ... British journal of cancer 95 (5), 587-592, 2006 | 262 | 2006 |
| Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples A Kotsakis, M Harasymczuk, B Schilling, V Georgoulias, A Argiris, ... Journal of immunological methods 381 (1-2), 14-22, 2012 | 221 | 2012 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 214 | 2017 |
| Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck A Argiris, AP Kotsakis, T Hoang, FP Worden, P Savvides, MK Gibson, ... Annals of oncology 24 (1), 220-225, 2013 | 162 | 2013 |
| Phase II study of everolimus (RAD001) in previously treated small cell lung cancer A Tarhini, A Kotsakis, W Gooding, Y Shuai, D Petro, D Friedland, ... Clinical Cancer Research 16 (23), 5900-5907, 2010 | 159 | 2010 |
| Front-line treatment of advanced non–small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial V Georgoulias, C Kouroussis, N Androulakis, S Kakolyris, MA Dimopoulos, ... Journal of clinical oncology 17 (3), 914-914, 1999 | 158 | 1999 |
| Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study A Karampeazis, A Voutsina, J Souglakos, N Kentepozidis, S Giassas, ... Cancer 119 (15), 2754-2764, 2013 | 145 | 2013 |
| Small cell lung cancer (SCLC): no treatment advances in recent years F Koinis, A Kotsakis, V Georgoulias Translational lung cancer research 5 (1), 39, 2016 | 144 | 2016 |
| Vaccination of patients with advanced non–small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide I Bolonaki, A Kotsakis, E Papadimitraki, D Aggouraki, G Konsolakis, ... Journal of clinical oncology 25 (19), 2727-2734, 2007 | 137 | 2007 |
| Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study C Emmanouilides, G Sfakiotaki, N Androulakis, K Kalbakis, ... BMC cancer 7, 1-7, 2007 | 136 | 2007 |
| A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients EK Vetsika, F Koinis, M Gioulbasani, D Aggouraki, A Koutoulaki, ... Journal of immunology research 2014, 2014 | 135 | 2014 |
| Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of … S Apostolaki, M Perraki, A Pallis, V Bozionelou, S Agelaki, P Kanellou, ... Annals of oncology 18 (5), 851-858, 2007 | 123 | 2007 |
| Cancer therapy and cardiovascular risk: focus on bevacizumab P Economopoulou, A Kotsakis, I Kapiris, N Kentepozidis Cancer management and research, 133-143, 2015 | 115 | 2015 |
| Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity A Matikas, D Mistriotis, V Georgoulias, A Kotsakis Critical reviews in oncology/hematology 110, 1-12, 2017 | 99 | 2017 |
| Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial MI Koukourakis, C Kourousis, M Kamilaki, S Koukouraki, ... European Journal of Cancer 34 (6), 838-844, 1998 | 97 | 1998 |
| Myeloid-derived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer EK Vetsika, A Koukos, A Kotsakis Cells 8 (12), 1647, 2019 | 96 | 2019 |
| Effect of first-line treatment on myeloid-derived suppressor cells’ subpopulations in the peripheral blood of patients with non–small cell lung cancer F Koinis, EK Vetsika, D Aggouraki, E Skalidaki, A Koutoulaki, ... Journal of Thoracic Oncology 11 (8), 1263-1272, 2016 | 93 | 2016 |
| Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients A Kotsakis, F Koinis, A Katsarou, M Gioulbasani, D Aggouraki, ... Scientific reports 6 (1), 39247, 2016 | 89 | 2016 |
| Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy J Souglakos, A Kalykaki, L Vamvakas, N Androulakis, K Kalbakis, ... Annals of oncology 18 (2), 305-310, 2007 | 87 | 2007 |
